Maxygen, Inc. (MAXY)
-NasdaqGS 2.38 
0.02(0.85%) 4:00PM EDT
| Prev Close: | 2.36 |
|---|
| Open: | 2.38 |
|---|
| Bid: | 2.38 x 10900 |
|---|
| Ask: | 2.39 x 4900 |
|---|
| 1y Target Est: | 15.00 |
|---|
| Beta: | 0.28 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 2.35 - 2.40 |
|---|
| 52wk Range: | 2.35 - 6.33 |
|---|
| Volume: | 21,195 |
|---|
| Avg Vol (3m): | 76,129 |
|---|
| Market Cap: | 66.14M |
|---|
| P/E (ttm): | 3.20 |
|---|
| EPS (ttm): | 0.74 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- MAXYGEN INC FinancialsEDGAR Online Financials(Fri, May 10)
- Maxygen Reports First Quarter 2013 Financial ResultsBusiness Wire(Fri, May 3)
- MAXYGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Fri, May 3)
- MAXYGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, Mar 12)
- Maxygen Reports Fourth Quarter and Year End 2012 Financial ResultsBusiness Wire(Tue, Mar 12)
- Maxygen Announces Tax Treatment of 2012 Cash DistributionBusiness Wire(Tue, Jan 29)
- MAXYGEN INC Files SEC form 8-K, Other EventsEDGAR Online(Fri, Nov 16)
- MAXYGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, Nov 6)
- Maxygen Announces Third Quarter 2012 Financial ResultsBusiness Wire(Tue, Nov 6)
- 5 Stocks Trading Below Net Cash - Part IXat Seeking Alpha(Tue, Oct 2)
- Watch Out For The One-Time Revenue Effectat Seeking Alpha(Fri, Sep 14)
- Maxygen Inc. Stock Downgraded (MAXY)at TheStreet(Tue, Sep 11)
- Maxygen Inc. Stock Upgraded (MAXY)at TheStreet(Tue, Aug 14)
- MAXYGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements andEDGAR Online(Tue, Aug 7)
- Maxygen Inc. Stock Upgraded (MAXY)at TheStreet(Tue, Jul 3)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 2.19 |
|---|
| Ex-Dividend Date: | 07-Sep-12 |
|---|
Analysts
| Annual EPS Est
(Dec-12)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Maxygen, Inc., a biopharmaceutical company, focuses on the discovery and development of protein pharmaceuticals for the treatment of disease and serious medical conditions in the United States.
View More